Most Read Articles
Elvira Manzano, 17 Oct 2017
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Kavitha G. Shekar, 14 Jun 2016
The incidence of type 1 diabetes mellitus (T1D) was found to be higher in juvenile idiopathic arthritis patients (JIA) compared with the general population, said German researchers at the European League Against Rheumatism Annual Congress (EULAR 2016) held in London, UK.
Elaine Tan, 29 Jun 2017

Tofacitinib, a first-in-class Janus kinase (JAK) inhibitor, shows promise as an oral treatment with quick onset of action and sustained efficacy in patients with psoriatic arthritis (PsA) who do not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). 

Dr. Priscilla Wong, Dr. Lydia Tam, Prof. LS Tam, 10 Nov 2017
This case report highlights that psoriatic arthritis is a heterogenous disease affecting multiple disease domains, and effective treatment requires thorough assessment of each of these different domains.

Elastic band resistance training improves muscle mass, physical function in older females

10 Feb 2018

Elastic band resistance training (ERT) is associated with improvements in muscle mass, physical function and muscle quality in elderly females, a recent study has shown.

Researchers randomized 56 elderly females (mean age 67.3±5.1 years) to receive 12 weeks of ERT (n=33) or a no-exercise control intervention (n=23). Lean mass, physical capacity and quality of life were assessed at baseline and at 3- and 9-month follow-up.

Relative to the controls, the ERT intervention resulted in significant improvements in appendicular lean mass at the 3-month (adjusted mean difference [MD], 0.99; 95 percent CI, 0.33–1.66; p<0.01) but not at the 9-month (adjusted MD, 0.49; –0.05 to 1.04) follow-up.

Appendicular mass index was significantly improved at both the 3-month (adjusted MD, 0.31; 0.03–0.61) and 9-month (adjusted MD, 0.21; 0.01–0.42; p<0.05 for both) follow-up. Total skeletal mass also significantly increased at both 3- and 9-month follow-up (adjusted MD, 0.70; 0.12–1.28; p<0.05 and adjusted MD, 0.72; 0.21–1.23; p<0.01, respectively).

The ERT intervention also improved physical capacity. At the 3-month follow-up, those who received the ERT walked faster by 0.14 m/s and reached further by 7.46 cm compared with controls. Both measures reached statistical significance (p<0.05 and p<0.001).

In the single leg stance test, balance was significantly greater by 9.71 s (p<0.001) in the ERT group. Scores in the Timed Up & Go test also improved significantly by 1.64 s (p<0.001).

The ERT group also showed significant improvements from baseline in the Medical Outcomes Study Short Form-36 Questionnaire scores at both the 3-month (MD, 13.00; 5.03–20.98; p<0.01) and 9-month (MD, 13.62; 6.47–20.76; p<0.001) follow-up.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 17 Oct 2017
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Kavitha G. Shekar, 14 Jun 2016
The incidence of type 1 diabetes mellitus (T1D) was found to be higher in juvenile idiopathic arthritis patients (JIA) compared with the general population, said German researchers at the European League Against Rheumatism Annual Congress (EULAR 2016) held in London, UK.
Elaine Tan, 29 Jun 2017

Tofacitinib, a first-in-class Janus kinase (JAK) inhibitor, shows promise as an oral treatment with quick onset of action and sustained efficacy in patients with psoriatic arthritis (PsA) who do not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). 

Dr. Priscilla Wong, Dr. Lydia Tam, Prof. LS Tam, 10 Nov 2017
This case report highlights that psoriatic arthritis is a heterogenous disease affecting multiple disease domains, and effective treatment requires thorough assessment of each of these different domains.